

**Orient Europharma announces monthly results:
up 10 percent in November**

Taipei, Taiwan, Dec. 7, 2009 – Orient Europharma Co. Ltd. (OE, Taiwan OTC: 4120) today announced financial results for November. OE reported Nov. sales of NT\$294 million – the second highest monthly sales figure this year. The amount is 12 percent higher year-on-year and 4.1 percent higher than corresponding figures for October.

Oncology drugs have become the main drivers in today's global pharmaceutical industry. OE's business development strategy also focuses on the oncology segment. The company's oncology sales grew 16 percent over the same month of last year.

Sales of OE's dermo-cosmetic products increased 30 percent year-on-year. The advent of autumn and winter typically coincides with a rise in skin problems such as dermatitis and dryness. Hence, these seasons typically bring about a boost in sales of hypoallergenic, moisturizing and anti-wrinkle skin care solutions, as well as injectable hyaluronic acid products. OE's dermo-cosmetic products cater to a wide array of consumers. The off-the-shelf approach to the sale of dermo-cosmetics further creates a huge business potential that bodes well for OE's fourth quarter performance.

OE next year will introduce two new drugs developed in-house that feature breakthrough treatments with reduced side effects and innovative formulations. These introductions will mitigate the periodic price reductions implemented by Taiwan's Bureau of National Health reimbursement scheme. As in recent years, governments in Europe, the United States, mainland China and Taiwan have made the health care and biotechnology industries a priority in their economic policies the market for OE's pharmaceutical products will, nevertheless, keep growing.

At the same time, OE continues to be the leader in Taiwan's infant milk powder and injectable hyaluronic acid segments. Sales in Hong Kong, China, Singapore, Malaysia and the Philippines have also shown steady growth.

Aside from holding on to its market positions in Taiwan, OE will continue to expand its presence in the rest of Asia. Its subsidiary Orient Pharma has also inked drug development agreements with various UK and US biopharmaceutical companies. OE plans to also expand its presence in Europe, the United States, Japan and other countries in line with the company's sustainable development strategy.

#